Human Luminex Screening Assay (LXSAH): R&D Systems

Human Luminex Assay

(5 citations)   
  • Assay Type
    Bead-based multiplex assay for the Luminex® platform
  • Format
    1 x 96-well microplate and polystyrene antibody-coated beads
  • Analytes Detected
    Please see table below.
  • Performance Validation
     
    Product Features

Luminex Assays are the most flexible bead-based multiplex assays that we offer. They allow up to 100 user-defined target analytes to be simultaneously profiled using cell culture supernates, serum, or plasma samples.

Features
  • User defines up to 100 analytes of interest
  • Wide selection of analytes
  • Requires a small sample volume (50 µL)
  • Mass-calibrated standards for consistent results with every new lot of material
  • Enough reagents for one 96-well plate
  • Quick turn-around time: Kits are typically shipped within 4-7 days of ordering.*

*Please allow additional time when placing orders through a distributor.

 

Kit Contents
  • Premixed antibody-coated bead cocktail
  • Premixed biotinylated detection antibody cocktail
  • Standard Cocktail(s)
  • Bead Diluent
  • Biotin Antibody Diluent
  • Standard/Sample Diluent
  • Wash Buffer
  • Streptavidin-PE
  • One Filter-bottom 96-well Microplate
  • Foil Plate Sealers
  • Mixing Bottle
  • Certificate of Analysis

 

Available Luminex Assays Analytes

The following chart indicates the bead region, sensitivity, high standard value, and recommended samples and their starting dilution for each analyte.

Analyte Sensitivity
(MDD)pg/mL
Standard
Curve Range (pg/mL)
Starting Sample Dilution Polystyrene
Bead Region
Cell Culture
Supernates
Serum Plasma
4-1BB/CD137 2.8 35.8-8,710 1:2 1:2 1:2 2
ADAMTS13 1,270 18,646-4,530,860 1:2 1:2 1:2 81
Adiponectin/Acrp30 148 842-204,700 1:2 1:200 1:200 25
AgRP/ART 0.183 5.97-1,450 1:2 1:2 1:2 23
ALDH1A1 7.10 118-28,560 1:2 1:50 1:50 3
alpha 1-Microglobulin, 29,563 147,826-35,921,600 1:2 1:2 1:2 4
Angiogenin 3.17 22.7-5,510 1:2 1:200 1:200 81
Angiopoietin-1 9.43 114-27,610 1:2 1:50 1:2 98
Angiopoietin-2 17.1 90.5-22,000 1:2 1:2 1:2 61
Angiopoietin-like 6 12.0 296-71,930 1:2 1:2 1:2 41
ApoA1 1,502 21,432-5,207,920 1:2 1:4,000 1:4,000 42
APRIL 7.95 202-49,200 1:2 1:2 1:2 24
Calbindin D 12.3 30.5-7,400 1:2 1:2 1:2 17
Carbonic Anhydrase IX/CA9 2.11 9.71-2,360 1:2 1:2 1:2 26
Cardiac Myoglobin 1.26 16.3-3,970 1:2 1:50 1:50 74
Total Cathepsin S 9.65 126-30,710 1:2 1:2 1:2 68
CCL1/I-309 0.119 4.57-1,110 1:2 1:2 1:2 44
CCL2/MCP-1 9.9 31.9-7,740 1:2 1:2 1:2 10
CCL3/MIP-1 alpha 16.2 90.9-22,090 1:2 1:2 1:2 18
CCL4/MIP-1 beta 5.8 133.1-32,350 1:2 1:2 1:2 20
CCL5/RANTES 1.8 20.7-5,020 1:2 1:50 1:50 19
CCL7/MCP-3 3.15 35.3-8,570 1:2 1:2 1:2 69
CCL8/MCP-2 1.82 16.5-4,000 1:2 1:2 1:2 71
CCL11/Eotaxin 14.6 60.7-14,750 1:2 1:2 1:2 100
CCL14/HCC-1/ HCC-3 31.8 147-35,610 1:2 1:50 1:50 12
CCL17/TARC 6.47 85.6-20,790 1:2 1:2 1:2 38
CCL20/MIP-3 alpha 3.39 7.9-1,920 1:2 1:2 1:2 66
CCL21/6Ckine 9.06 35.4-8,600 1:2 1:2 1:2 41
CCL22/MDC 8.45 48.8-11,870 1:2 1:2 1:2 68
CCL25/TECK, 1.22 50.7-12,320 1:2 1:2 1:2 27
CD23/Fc epsilon RII 16.5 167-40,550 1:2 1:2 1:2 24
CD40 Ligand 34.7 212-51,430 1:2 1:2 1:2 82
CD117/c-kit/SCF R 93.5 755-183,370 1:2 1:2 1:2 6
CD163 530 5,196-1,262,520 1:2 1:2 1:2 62
CEACAM-1/CD66a 158 2,007-487-620 1:2 1:2 1:2 83
CEA/CEACAM-5 12.9 168-40,850 1:2 1:2 1:2 65
Chemerin 69.0 369-89,710 1:2 1:2 1:2 46
Chitinase 3-like 1/ YKL-40 3.3 352-85,610 1:2 1:2 1:2 57
Collagen I alpha 1/COL1A1 0.580 13.0-3,170 1:2 1:50 1:50 45
Collagen IV alpha 1 10.2 93-22,600 1:2 1:2 1:2 83
C9 2,097 26,071-6,335,280 1:2 1:50 1:50 28
Contactin-1 3.58 230-55,890 1:2 1:2 1:2 29
CRP 116 104-25,200 1:2 1:200 1:200 38
CX3CL1/ Fractalkine 64.8 1,114-270,610 1:2 1:2 1:2 26
CXCL1/Gro alpha 5.3 151-12,200 1:2 1:2 1:2 49
CXCL2/Gro beta 7.86 49.2-11,960 1:2 1:2 1:2 11
CXCL5/ENA-78 8.2 50.2-12,200 1:2 1:2 1:2 31
CXCL8/IL-8 1.8 4.4-1,060 1:2 1:2 1:2 5
CXCL9/MIG 18.4 450-109,310 1:2 1:2 1:2 30
CXCL10/IP-10 1.18 2.8-690 1:2 1:2 1:2 58
CXCL12/SDF-1 alpha 17.0 151-36,720 1:2 1:2 1:2 60
CXCL14/BRAK 26.0 97.1-23,600 1:2 1:2 1:2 42
Cystatin C 103 666-161,910 1:2 1:50 1:50 84
DR3/TNFRSF25 58.6 545-132,330 1:2 1:2 1:2 95
EGF 8.9 18.7-4,550 1:2 1:2 1:2 60
Endostatin 27.3 153-37,200 1:2 1:2 1:2 46
Endothelin-1 1.31 11.6-2,810 1:2 1:2 1:2 50
EN-RAGE/S100A12 1.77 28.4-6,900 1:2 1:50 1:50 31
EpCAM/TROP1 2.22 48.6-11,820 1:2 1:2 1:2 32
ErbB2/Her2 36.6 144-34,900 1:2 1:2 1:2 47
ErbB3/Her3 9.42 290-70,410 1:2 1:2 1:2  
ESAM 7.67 45.3-11,000 1:2 1:2 1:2 43
Fas Ligand 1.23 17-4,130 1:2 1:2 1:2 73
Ferritin 1.29 25.8-6,270 1:2 1:50 1:50 46
Fetuin A/AHSG 241 5,903-1,434,500 1:2 1:4,000 1:4,000 86
FGF acidic 4.88 8.9-2,170 1:2 1:2 1:2 87
FGF basic NEW 6.5 1.89-460 1:2 1:2 1:2 28
FGF-13 1B 20.6 216-52,540 1:2 1:2 1:2 10
FGF-23 10.2 12.1-2,940 1:2 1:2 1:2 84
Fibroblast Activation Protein 0.667 22.6-5,480 1:2 1:50 1:50 47
Fibronectin 171 3,761-914,030 1:2 1:4,000 1:4,000 85
FLRG 52.0 962-233,660 1:2 1:2 1:2 63
Follistatin-like 1 281 1,207-293,190 1:2 1:2 1:2 34
Galectin-3BP/ MAC-2BP 194 830-201,700 1:2 1:50 1:50 48
Gas6 3.58 109-26,560 1:2 1:50 1:50 79
G-CSF 4.1 21.5-5,230 1:2 1:2 1:2 33
GITR 11.1 152-37,010 1:2 1:2 1:2 87
Glucagon 11.7 42.3-10,270 1:2 1:2 1:2 10
GM-CSF 4.1 12.5-3,030 1:2 1:2 1:2 27
gp130 11.2 371-90,180 1:2 1:2 1:2 54
Granzyme A 2.18 27.4-6,650 1:2 1:2 1:2 78
Growth Hormone 12.2 75.8-18,430 1:2 1:2 1:2 24
HB-EGF 0.4 11.9-2,900 1:2 1:2 1:2 59
HE4/WFDC-2 10.8 198-48,000 1:2 1:2 1:2 88
HGF 1.0 40.7-9,890 1:2 1:2 1:2 42
HGF R/c-MET 2.48 165-40,120 1:2 1:50 1:50 89
HTRA2/Omi 0.955 55.8-13,550 1:2 1:2 1:2 91
ICAM-1 87.9 6,615-1,607,350 1:2 1:2 1:2 30
IFN-beta 0.476 14.1-3,430 1:2 1:2 1:2 48
IFN-gamma 0.40 49.2-11,950 1:2 1:2 1:2 14
IGFBP-1 42.6 139-33,690 1:2 1:2 1:2 70
IGFBP-2 116 764-185,720 1:2 1:50 1:50 11
IGFBP-4 16.2 136-33,070 1:2 1:2 1:2 30
IGFBP-6 2.38 38.3-9,308 1:2 1:200 1:200 12
IGFBP-rp1/IGFBP-7 118 385-93,600 1:2 1:2 1:2 49
IL-1 alpha 0.9 5.02-1,220 1:2 1:2 1:2 21
IL-1 beta 0.8 16.3-3,960 1:2 1:2 1:2 13
IL-1 ra 18.0 27.5-6,690 1:2 1:2 1:2 15
IL-1 RI 4.49 119-28,940 1:2 1:2 1:2 90
IL-1 RII 18.0 275-66,710 1:2 1:2 1:2 89
IL-2 1.80 31.1-7,560 1:2 1:2 1:2 24
IL-2 R alpha/CD25 1.30 27-6,570 1:2 1:2 1:2 77
IL-3 11.6 84.5-20,530 1:2 1:2 1:2 55
IL-4 9.3 16.3-3,950 1:2 1:2 1:2 22
IL-5 0.5 5.84-1,420 1:2 1:2 1:2 32
IL-6 1.7 4.5-1,100 1:2 1:2 1:2 2
IL-10 1.6 3.6--880 1:2 1:2 1:2 9
IL-11 24.7 516-125,410 1:2 1:2 1:2 94
IL-12/23 p40 35.2 383-93,100 1:2 1:2 1:2 93
IL-12 p70 20.2 127-30,920 1:2 1:2 1:2 35
IL-13 32.4 455-110,520 1:2 1:2 1:2 27
IL-15 1.01 6.3-1,540 1:2 1:2 1:2 97
IL-17A 1.8 9.26-2,250 1:2 1:2 1:2 23
IL-17E/IL-25 27.7 369-89,590 1:2 1:2 1:2 14
IL-18 1.93 54.6-13,260 1:2 1:2 1:2 50
IL-18 BPa 1.9 99.3-24,120 1:2 1:2 1:2 54
IL-21 0.869 29.4-7,140 1:2 1:2 1:2 51
IL-22 11.7 16.3-3,970 1:2 1:2 1:2 69
IL-23 11.4 229-55,600 1:2 1:2 1:2 48
IL-33 1.8 47.5-11,550 1:2 1:2 1:2 53
IL-34 18.7 164-39,950 1:2 1:2 1:2 73
Total Inhibin 21.7 50.3-12,220 1:2 1:2 1:2 75
Insulin C-Peptide 2.83 44.7-10,860 1:2 1:2 1:2 6
ITIH4 141 1,069-259,700 1:2 1:4,000 1:4,000 51
Kallikrein 3/PSA 8.30 73.9-17,950 1:2 1:2 1:2 56
Kallikrein 5 81.5 108-26,230 1:2 1:2 1:2 57
Kallikrein 6/Neurosin 5.45 277-67,240 1:2 1:2 1:2 35
Lactoferrin 201 573-139,190 1:2 1:50 1:50 69
LBP 83.9 747-181,524 1:2 1:200 1:200 36
Leptin 10.2 493-119,830 1:2 1:2 1:2 30
LIGHT 0.691 11.4-2,770 1:2 1:2 1:2 15
Lipocalin-2/NGAL 29.2 140-33,920 1:2 1:50 1:50 88
Lumican 497 9,458-2,298,400 1:2 1:50 1:50 52
MAdCAM-1 51.3 1,074-260,896 1:2 1:2 1:2 16
MBL 1.78 44.2-10,730 1:2 1:4,000 1:4,000 37
MCAM/CD146 3.5 215-52,240 1:2 1:2 1:2 96
M-CSF 33.3 514-124,810 1:2 1:2 1:2 28
MIA 36.6 211-51,220 1:2 1:2 1:2 39
MICA 5.35 68.4-16,620 1:2 1:2 1:2 2
MICB 35.8 108-26,290 1:2 1:2 1:2 4
Midkine 6.64 42.8-10,410 1:2 1:2 1:2 39
MMP-1 2.7 33-8,020 1:2 1:2 1:2 6
MMP-2 108 296-71,930 1:2 1:50 1:50 7
MMP-3 5.3 81.5-19,810 1:2 1:2 1:2 4
MMP-7 23.2 346-84,090 1:2 1:2 1:2 8
MMP-8 34.2 454.5-110,440 1:2 1:2 1:2 12
MMP-9 13.6 133.6-32,460 1:2 1:50 1:50 3
MMP-10 1.30 53.7-13,050 1:2 1:2 1:2 52
MMP-13 19.0 138.7-33,700 1:2 1:2 1:2 16
MSP-MST1 26.9 103-25,000 1:2 1:200 1:200 53
NAGLU 7.68 398-96,700 1:2 1:2 1:2 67
N-Cadherin 55.1 1,015-246,650 1:2 1:50 1:50 72
NCAM-1 412 872-212,000 1:2 1:2 1:2 54
Nectin-4 17.2 81.5-19,810 1:2 1:2 1:2 63
Neuropilin-1 5.31 86.2-20,950 1:2 1:50 1:50 17
NT-4 1.30 9.05-2,200 1:2 1:2 1:2 56
NT-Pro-ANP 66.2 271-65,820 1:2 1:2 1:2 17
Osteopontin 413 1,804-438,290 1:2 1:2 1:2 89
Osteoprotegerin, 3.62 81.4-19,770 1:2 1:2 1:2 62
PARK5/UCH-L1 60.7 2,982-241,550 1:2 1:2 1:2 59
Park7/DJ-1 49.1 279-67,880 1:2 1:2 1:2 70
PDGF-AA 0.747 5.6-1,350 1:2 1:50 1:2 90
PDGF-AB 3.28 35.4-8,605 1:2 1:2 1:2 18
PDGF-BB 0.200 13.6-3,310 1:2 1:50 1:50 59
PLA2G7/PAF-AH/Lp-PLA2 326 3,647-886,100 1:2 1:2 1:2 77
PlGF 3.9 1.9-470 1:2 1:2 1:2 91
PP14/Glycodelin 318 874-212,310 1:2 1:2 1:2 19
Properdin, 148 2,330-566,160 1:2 1:200 1:200 53
Proprotein Convertase 9/ PCSK9 246 810-196,860 1:2 1:2 1:2 76
Protein S/PROS1 8.15 128-31,030 1:2 1:4,000 1:4,000 20
Proteinase 3/PRTN3 1.41 7.41-1,800 1:2 1:50 1:50 45
P-Selectin 9.0 199-48,330 1:2 1:2 1:2 29
Reg3A, 3.71 253-61,550 1:2 1:2 1:2 97
Relaxin-2 6.72 69.1-16,790 1:2 1:2 1:2 34
S100B 4.34 93.4-22,700 1:2 1:2 1:2 59
SCGF/CLEC11a 12.6 369-89,680 1:2 1:2 1:2 98
Serpin A7/TBG 28.4 775-188,420 1:2 1:200 1:200 36
Serpin A10/ZPI 20.8 955-232,088 1:2 1:200 1:200 55
Serpin A12/Vaspin 2.85 54.1-13,150 1:2 1:2 1:2 56
Serpin B3/SCCA1 17.6 81-19,690 1:2 1:2 1:2 57
Serpin F1/PEDF 3.66 143-67,793 1:2 1:2 1:2 21
SLPI 31.4 732-177,950 1:2 1:2 1:2 99
ST2/IL-33 R 29.9 569-138,260 1:2 1:2 1:2 55
Syndecan-1/CD138 15.6 173-42,110 1:2 1:2 1:2 64
Syndecan-4 1.69 56.2-13,660 1:2 1:2 1:2 100
Tau 4.49 108-26,150 1:2 1:2 1:2 66
TfR 67.5 395-95,990 1:2 1:200 1:200 3
Thrombospondin-2 30.7 225-54,680 1:2 1:2 1:2 80
Thymidine Kinase 1/TK1 6.64 48.2-11,710 1:2 1:2 1:2 58
Tie-2 211 614-149,166 1:2 1:2 1:2 86
TIMP-1 3.42 54.7-13,280 1:2 1:50 1:50 95
TNF-alpha 1.2 8.9-2,160 1:2 1:2 1:2 1
TNF RI 41.0 221-53,820 1:2 1:2 1:2 93
Tpo 24.8 411-99,910 1:2 1:2 1:2 34
TRANCE/RANK L 4.68 11.9-2,890 1:2 1:2 1:2 78
TREM-1 10.7 115-28,060 1:2 1:2 1:2 40
ULBP-1 6.41 48.5-11,790 1:2 1:2 1:2 6
ULBP-2/5/6 62.3 168-40,870 1:2 1:2 1:2 8
ULBP-3 8.42 166-40,390 1:2 1:2 1:2 10
ULBP-4/RAET1E 26.0 64.4-15,650 1:2 1:2 1:2 12
Uteroglobin 3.98 31.5-7,650 1:2 1:50 1:50 40
VAP-1 5.37 86.5-21,010 1:2 1:50 1:50 72
VCAM-1 238 8,317-2,021,050 1:2 1:2 1:2 36
VEGF-A 2.1 8.5-2,070 1:2 1:2 1:2 11
VEGF-C 5.46 57.0-13,860 1:2 1:2 1:2 22
VEGF-D 11.1 53-12,890 1:2 1:2 1:2 96
VEGF R1 5.68 72.1-17,530 1:2 1:2 1:2 84
VEGF R2 7.4 154-37,400 1:2 1:2 1:2 1
Vitamin D Binding Protein 227 6,655-1,617,080 1:2 1:50 1:50 20
XCL1/Lymphotactin 53.0 90.5-7,330 1:2 1:2 1:2 22

*A standard curve must be generated each time an assay is run, utilizing values from the Certificate of Analysis provided with each Luminex Assay.

 

Assays for the Luminex platform are offered as High Performance Assays or Assays. The Luminex High Performance Assays are fully validated panels with a focused selection of analytes. They are available in We Mix, You Mix, and Predetermined formats. The Luminex Assays allows for the maximum number of analytes in a multiplex and is supplied as a premixed kit. View a table comparing the features and benefits of these bead-based multiplex assays.

Trademarks and registered trademarks are the property of their respective company.

Citations:

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

5 Citations: Showing 1 - 5
Filter your results:

Species
Sample Type
  1. Biomarker dynamics in B-cell lymphoma: a longitudinal prospective study of plasma samples up to 25 years before diagnosis
    Authors: F Sp„th, C Wibom, EJ Krop, AS Johansson, IA Bergdahl, R Vermeulen, B Melin
    Cancer Res, 2017;0(0):.
    Species: Human
    Sample Type: Plasma
  2. Thiazolides Elicit Anti-Viral Innate Immunity and Reduce HIV Replication
    Authors: Daria Trabattoni
    Sci Rep, 2016;6(0):27148.
    Species: Human
    Sample Type: Cell Culture Supernates
  3. The Systemic Profile of Soluble Immune Mediators in Patients with Myelodysplastic Syndromes
    Int J Mol Sci, 2016;17(7):.
    Species: Human
    Sample Type: Serum
  4. Distinct emphysema subtypes defined by quantitative CT analysis are associated with specific pulmonary matrix metalloproteinases
    Respir Res, 2016;17(1):92.
    Species: Human
    Sample Type: BALF
  5. Simultaneous detection of multiple cytokines and chemokines from nonhuman primates using luminex technology.
    Authors: Giavedoni L
    J Immunol Methods, 2005;301(1):89-101.
    Species: Primate - Chlorocebus pygerythrus (Vervet Monkey)
    Sample Type: Cell Culture Supernates
Luminex Instruments
Description Application Cat# Citations Images  

Luminex LX-200 Instrument with xPONENT 3.1

LX200-XPON31-RUO
View Sizes & Prices
Catalog# Size Price Stock Quantity
Loading Information....

Luminex LX-200 Instrument with xPONENT 3.1

LX200-XPON31
View Sizes & Prices
Catalog# Size Price Stock Quantity
Loading Information....

Have you used Human Luminex Assay?

Submit a review and receive a $25US/€18/£15/$25CAN amazon gift card if you include an image - $10US/€7/£6/$10CAN Amazon card for reviews without an image. Limited to verified customers in USA, Canada and Europe.

FAQs

  1. What is the difference between the Luminex® Screening Assay and the Luminex® Performance Assay?

    • In general, the sensitivity of Luminex® Screening Assays and Luminex® Performance Assays is similar. A Performance Assay consists of select analytes which have been thoroughly tested and validated together as a panel. The diluents provided in the performance kits and assay conditions have been optimized for best results with the analytes on the same panel. The Performance Assay is the most precise, reproducible and accurate Luminex tool offered by R&D Systems.

      The Screening Assay option is a flexible tool, providing the uncommon opportunity to customize by mixing and matching analytes across different panels. Although not as extensively tested as the Performance Assays, analytes on a Screening Assay are tested together when built and a final quality control test on each Screening Assay is performed prior to release. Since each Screening Assay is unique and built-to-order, additional days are required for order fulfillment and it is not characterized by the same level of optimization and validation testing as with the Performance assays.  

      For low abundance cytokines, High Sensitivity panels are available for Performance Assay, which are not available for Screening Assay. 

      The quality of the R&D Systems® Screening Assays is similar to the Luminex® Assays offered by other vendors. The following chart compares the different types of Luminex® Assays R&D Systems offers and may serve as a general guide for choosing which assay format is suitable to your experimental goals. 

      //www.rndsystems.com/products/which-luminex-assay-right-me

       

View all Luminex Assay FAQs

Order Details

Size Price Stk
LXSAH
1 Kit
Build Now

Build your own with our Luminex Assay Customization Tool.

Contact Information

R&D Systems Guarantee

Feedback

Customer Information